Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Cancer Res. 2015 Feb 3;75(7):1366–1375. doi: 10.1158/0008-5472.CAN-14-1849

Fig. 5. Mcl-1 overexpression confers resistance to ABT-263 and ABT-199.

Fig. 5

ALL-2 cells overexpressing Mcl-1 (ALL-2/Mcl-1) were prepared by retroviral transduction, as described in Materials and Methods. A. Extracts were made from ALL-2 and ALL-2/Mcl-1 cells and subjected to immunoblotting for Bcl-2, Bcl-xL or Mcl-1. GAPDH was used as a loading control. B. ALL-2 or ALL-2/Mcl-1 cells were treated with vehicle (100% viability) or increasing concentrations of ABT-263 for 72 h and cell viability was assessed by MTT assay as described in Materials and Methods. Results are given as mean ± s.d. (n = 6). C. ALL-2 or ALL-2/Mcl-1 cells were treated with vehicle (100% viability) or increasing concentrations of ABT-199 for 72 h and cell viability was assessed by MTT assay as described in Materials and Methods. Results are given as mean ± s.d. (n = 6). D. Overexpressed Mcl-1 sequesters Bim. Extracts from ALL-2 (lane 2) or ALL-2/Mcl-1 (lane 3) cells were immunoprecipitated with either Mcl-1 antibody (left panel) or Bcl-2 antibody (right panel) as indicated and subjected to immunoblotting for Mcl-1 and Bim (left) or Bcl-2 and Bim (right). Mock immunoprecipitations in the absence of primary antibody were also performed, using extracts from ALL-2 cells (lane 1 in each panel). The asterisk indicates a non-specific band.